Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium
- PMID: 15800680
- DOI: 10.1007/BF03032403
Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium
Abstract
To evaluate the role of c-jun and c-myc proto-oncogenes in normal, hyperplastic and neoplastic endometrium in relation to estrogen receptor (ER) status and to investigate whether these genes can be related to other histopathological features of endometrial carcinoma, 32 endometrial carcinomas, 38 endometrial hyperplasias and 22 cyclic endometria (10 proliferative and 12 secretory) were evaluated histologically. Endometrial hyperplasia cases were classified as simple and complex hyperplasia without atypia, and atypical hyperplasia. Endometrial carcinoma cases were subtyped according to the International Society of Gynecological Pathologists. Modified FIGO system was used for both grading and staging. Immunohistochemical examination was performed using antibodies to ER-alpha, c-myc and c-jun with streptavidin-biotin-peroxidase technique. The mean percentage of ER-alpha positive cells changed cyclically during the menstrual cycle, and it was the highest (96%) and the lowest (31.6%) in proliferative and carcinomatous endometrium, respectively. There was a statistically significant difference between proliferative and secretory phases and proliferative and carcinomatous endometrium in relation to ER-alpha staining (p<0.05). There was also a statistically significant difference with respect to ERalpha reactivity between secretory phase and each hyperplastic group, as well as between the carcinoma group and each hyperplastic group (p<0.05). Although not significant, the mean percentage of c-myc expressing cells in the carcinoma group was higher (15.3%) than that of proliferative phase and hyperplastic groups. The mean percentage of c-jun positive cells in proliferative endometrium was slightly higher than in secretory endometrium, and it was the highest in atypical hyperplastic endometrium (28.3%), but there was no statistically significant difference between the groups. In carcinoma cases, a positive correlation was observed between c-jun positivity and tumor grade (p=0.027, r=0.3908), but such a correlation with c-myc was not found. A positive correlation was detected between ER-alpha and c-myc expression (p=0.038, r=0.3686). A progressive loss of ER seems to be correlated with increasing malignant transformation. C-myc expression might play a role in the development of endometrial carcinoma via ER. The association between c-jun and ER appears to be lost in endometrial carcinoma. The relationship between c-myc, c-jun and ER appears to be altered in endometrial carcinoma compared to that of menstrual endometrium.
Similar articles
-
Apoptosis-related proteins and steroid hormone receptors in normal, hyperplastic, and neoplastic endometrium.Int J Gynecol Pathol. 2002 Oct;21(4):375-82. doi: 10.1097/00004347-200210000-00007. Int J Gynecol Pathol. 2002. PMID: 12352186
-
Expression of receptor-binding cancer antigen expressed on SiSo cells and estrogen receptor subtypes in the normal, hyperplastic, and carcinomatous endometrium.Int J Gynecol Cancer. 2008 Jan-Feb;18(1):152-8. doi: 10.1111/j.1525-1438.2007.00966.x. Epub 2007 Apr 26. Int J Gynecol Cancer. 2008. PMID: 17466050
-
Significantly decreased P27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression).Pathol Oncol Res. 2004;10(2):89-97. doi: 10.1007/BF02893462. Epub 2004 Jun 9. Pathol Oncol Res. 2004. PMID: 15188025
-
Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer.APMIS. 2019 Sep;127(9):597-606. doi: 10.1111/apm.12977. APMIS. 2019. PMID: 31237034
-
Melanoma Cell Adhesion Molecule (CD 146) in Endometrial Physiology and Disorder.Adv Exp Med Biol. 2025;1474:131-148. doi: 10.1007/5584_2024_826. Adv Exp Med Biol. 2025. PMID: 39400880 Review.
Cited by
-
Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells.Endocrinology. 2008 Aug;149(8):3909-19. doi: 10.1210/en.2008-0286. Epub 2008 May 1. Endocrinology. 2008. PMID: 18450952 Free PMC article.
-
New concepts for an old problem: the diagnosis of endometrial hyperplasia.Hum Reprod Update. 2017 Mar 1;23(2):232-254. doi: 10.1093/humupd/dmw042. Hum Reprod Update. 2017. PMID: 27920066 Free PMC article. Review.
-
Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future.Front Pharmacol. 2023 Sep 21;14:1225951. doi: 10.3389/fphar.2023.1225951. eCollection 2023. Front Pharmacol. 2023. PMID: 37808197 Free PMC article. Review.
-
Network Pharmacology and Molecular Docking Approach to Reveal the Immunotherapeutic Mechanism of Cuscutae Semen in Treating Thin Endometrium.J Immunol Res. 2022 Sep 22;2022:4333128. doi: 10.1155/2022/4333128. eCollection 2022. J Immunol Res. 2022. PMID: 36249421 Free PMC article.
-
The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth.Biomed Res Int. 2014;2014:713263. doi: 10.1155/2014/713263. Epub 2014 Aug 13. Biomed Res Int. 2014. PMID: 25221777 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous